Cancers (Sep 2022)
Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
- Jerzy Jaroszewicz,
- Justyna Kowalska,
- Małgorzata Pawłowska,
- Magdalena Rogalska,
- Dorota Zarębska-Michaluk,
- Marta Rorat,
- Beata Lorenc,
- Piotr Czupryna,
- Katarzyna Sikorska,
- Anna Piekarska,
- Anna Dworzańska,
- Izabela Zaleska,
- Włodzimierz Mazur,
- Dorota Kozielewicz,
- Krzysztof Kłos,
- Regina Podlasin,
- Grzegorz Angielski,
- Barbara Oczko-Grzesik,
- Magdalena Figlerowicz,
- Bartosz Szetela,
- Beata Bolewska,
- Paulina Frańczak-Chmura,
- Robert Flisiak,
- Krzysztof Tomasiewicz
Affiliations
- Jerzy Jaroszewicz
- Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, Poland
- Justyna Kowalska
- Department of Adult’s Infectious Diseases, Medical University of Warsaw, Hospital for Infectious Diseases, 02-091 Warsaw, Poland
- Małgorzata Pawłowska
- Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Torun, Poland
- Magdalena Rogalska
- Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-809 Bialystok, Poland
- Dorota Zarębska-Michaluk
- Department of Infectious Diseases, Jan Kochanowski University, 25-317 Kielce, Poland
- Marta Rorat
- Department of Forensic Medicine, Wrocław Medical University, 50-367 Wroclaw, Poland
- Beata Lorenc
- Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, 80-210 Gdansk, Poland
- Piotr Czupryna
- Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, 15-809 Bialystok, Poland
- Katarzyna Sikorska
- Division of Tropical and Parasitic Diseases, Faculty of Health Sciences, Medical University of Gdańsk, 80-210 Gdansk, Poland
- Anna Piekarska
- Department of Infectious Diseases and Hepatology, Medical University of Łódź, 90-549 Lodz, Poland
- Anna Dworzańska
- Department of Infectious Diseases and Hepatology, Medical University of Lublin, 20-059 Lublin, Poland
- Izabela Zaleska
- Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland
- Włodzimierz Mazur
- Clinical Department of Infectious Diseases in Chorzów, Medical University of Silesia, 41-500 Katowice, Poland
- Dorota Kozielewicz
- Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Torun, Poland
- Krzysztof Kłos
- Department of Infectious Diseases and Allergology, Military Institute of Medicine, 04-141 Warsaw, Poland
- Regina Podlasin
- Hospital for Infectious Diseases, The IVth Department, 01-201 Warsaw, Poland
- Grzegorz Angielski
- 7th Navy Hospital, 80-305 Gdansk, Poland
- Barbara Oczko-Grzesik
- Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, Poland
- Magdalena Figlerowicz
- Department of Infectious Diseases and Child Neurology, Poznan University of Medical Sciences, 60-572 Poznan, Poland
- Bartosz Szetela
- Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, 50-367 Wroclaw, Poland
- Beata Bolewska
- Department of Infectious Diseases, Poznań University of Medical Sciences, 61-701 Poznan, Poland
- Paulina Frańczak-Chmura
- Department of Children’s Infectious Diseases, Provincial Jan Boży Hospital, 20-089 Lublin, Poland
- Robert Flisiak
- Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-809 Bialystok, Poland
- Krzysztof Tomasiewicz
- Department of Infectious Diseases and Hepatology, Medical University of Lublin, 20-059 Lublin, Poland
- DOI
- https://doi.org/10.3390/cancers14194720
- Journal volume & issue
-
Vol. 14,
no. 19
p. 4720
Abstract
Data on the use of remdesivir, the first antiviral agent against SARS-CoV-2, are limited in oncologic patients. We aimed to analyze contributing factors for mortality in patients with malignancies in the real-world CSOVID-19 study. In total, 222 patients with active oncological disorders were selected from a nationwide COVID-19 study of 4890 subjects. The main endpoint of the current study was the 28-day in-hospital mortality. Approximately half of the patients were male, and the majority had multimorbidity (69.8%), with a median age of 70 years. Baseline SpO2 2 (4.621, p = 0.02), whereas SpO2 decreased the odds of death at baseline (0.479 per 5%, p = 0.002) and the use of remdesivir (0.425, p = 0.03). This study shows that patients with COVID-19 and malignancy benefit from early remdesivir therapy, resulting in a decrease in early mortality by 80%. The prognosis was worsened by low glomerular filtration rate and low peripheral oxygen saturation at baseline underlying the role of kidney protection and early hospitalization.
Keywords
